what's the average weight loss on semaglutide Change With Semaglutide for Weight Loss: How

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for two primary indications: type 2 diabetes mellitus (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)

What I didn't say to them: "I've already spent $341 trying to make myself incapable of eating food, and now here I am, while you're enjoying your meal, sitting here and thinking about how sick I am even at the thought of smelling food." By week 3, I'd lost 8 pounds, and the fit of my jeans had changed

The fundamental difference lies in their receptor targeting: Rybelsus activates only GLP-1 receptors, while Mounjaro works as a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors

Recent research clearly shows that obesity is a chronic disease in its own right

It affects an estimated 6% of adults and over 30% of people with obesity or diabetes

Retatrutide works as a powerful triple-agonist, meaning it works on on three key hormone receptors: The human glucagon receptor (GCGR) The glucose-dependent insulinotropic polypeptide receptor (GIP) The glucagon-like peptide-1 receptor (GLP-1) This unique receptor profile allows retatrutide to effectively: Regulate appetite, feelings of fullness, and gastric emptying Regulate metabolism Regulate blood sugar levels Retatrutide activates the GIP, GLP-1, and GCG receptors simultaneously, leading to better weight loss and cardiometabolic benefits compared to targeting a single receptor